JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says

When Novartis scooped up The Medicines Company and its promising cholesterol drug inclisiran back in late 2019, the company jumped into a field where some of its pharma rivals had struggled to meet expectations over the years. Now, with approvals on both sides of the Atlantic, Novartis is busy rewriting the drug launch playbook in cardiovascular disease.